crohn s disease

Compugen Ltd. (NASDAQ: CGEN) 45.5% HIGHER; announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease, a commonly used term covering ulcerative colitis and Crohn's disease. Click here for the full report.

XOMA Ltd. (Nasdaq: XOMA) 35.3% HIGHER; following yesterday's late day spike on news that XOMA's bacterial cell expression technology licensee UCB S.A. has received FDA approval to market CIMZIA(r) (certolizumab pegol).

XOMA will receive royalty payments on sales of CIMZIA for this indication and will continue to receive royalties on sales of CIMZIA for the treatment of moderate to severe Crohn's disease, for which it was approved in April 2008.

Momentum is continuing today as news hit that Zymeworks has entered into a research agreement with XOMA Ltd.